Renaissance Technologies LLC Has $735,000 Holdings in NextCure, Inc. (NASDAQ:NXTC)

Renaissance Technologies LLC lifted its stake in NextCure, Inc. (NASDAQ:NXTC) by 15.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 462,144 shares of the company’s stock after acquiring an additional 61,744 shares during the period. Renaissance Technologies LLC owned approximately 1.65% of NextCure worth $735,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cable Car Capital LLC acquired a new stake in NextCure in the 4th quarter worth $702,000. Vanguard Group Inc. lifted its stake in shares of NextCure by 9.3% in the first quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock valued at $2,202,000 after buying an additional 83,700 shares during the period. Finally, Affinity Asset Advisors LLC bought a new stake in shares of NextCure in the first quarter valued at about $3,031,000. Institutional investors own 42.65% of the company’s stock.

NextCure Price Performance

Shares of NextCure stock opened at $1.38 on Wednesday. NextCure, Inc. has a 52-week low of $0.98 and a 52-week high of $2.57. The firm has a market capitalization of $38.60 million, a PE ratio of -0.61 and a beta of 0.79. The company’s fifty day moving average price is $1.48 and its two-hundred day moving average price is $1.58.

NextCure (NASDAQ:NXTC) last posted its earnings results on Thursday, August 1st. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.19). Analysts predict that NextCure, Inc. will post -1.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $4.00 price objective on shares of NextCure in a research report on Friday, August 2nd.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.